ZEG.DE

AstraZeneca PLC [ZEG.DE] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ZEG.DE Stock Summary

Earnings have grown 18.53% per last year.

ZEG.DE's dividend payments are well covered by cash flows with cash payout ratio of 78.75%.

Earnings are expected to fall -5.1% next year

ZEG.DE has less than 1 year of cash runway

Debt-to-Equity ratio of 1.7 is considered moderate, deeper research suggested.

Top 10 Correlated ETFs

ZEG.DE

Top 10 Correlated Stocks

ZEG.DE

In the News

ZEG.DE Financial details

Company Rating

Strong Buy

Market Cap

215.9B

Income

4.7B

Revenue

43.84B

Book val./share

23.1

Cash/share

4.17

Dividend

2.39

Dividend %

1.63%

Employees

83.5K

Optionable

Shortable

Yes

Earnings

31 Mar 2023

P/E

48.24

Forward P/E

13.49

PEG

0.13

P/S

5.18

P/B

6.34

P/C

32.81

P/FCF

37.65

Quick Ratio

0.26

Current Ratio

0.9

Debt / Equity

1.7

LT Debt / Equity

0.77

EPS (TTM)

3.03

EPS next Y

10.14

EPS next Q

EPS this Y

2550%

EPS next Y

234.77%

EPS next 5Y

234.77%

EPS last 5Y

4.51%

Revenue last 5Y

14.96%

Revenue Q/Q

-2.93%

EPS Q/Q

100%

SMA20

SMA50

8.8%

SMA100

3.03%

Inst Own

Inst Trans

ROA

ROE

13%

ROC

0.06%

Gross Margin

75%

Oper. Margin

Profit Margin

11%

Payout

94%

Shs Outstand

1.55B

Shs Float

1.54B

Target Price

52W Range

109.35-140.45

52W High

-2.29%

52W Low

+25.5%

RSI

Rel Volume

0.22

Avg Volume

6.27K

Volume

1.37K

Perf Week

2.32%

Perf Month

2.24%

Perf Quarter

6.92%

Perf Half Y

4.79%

Beta

0.178723

Volatility

1.1%, 1.64%

Prev Close

0.04%

Price

136.8

Change

0.44%

ZEG.DE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	17.43	18.74	20.29	26.39	28.65
Net income per share	1.7	1.03	2.44	0.08	2.12
Operating cash flow per share	2.07	2.28	3.66	4.21	6.34
Free cash flow per share	0.98	0.39	1.67	2.65	4.68
Cash per share	4.38	4.78	6.09	4.51	4.14
Book value per share	9.84	10.09	11.91	27.69	23.93
Tangible book value per share	-15.49	-13.76	-13.07	-16.29	-14.26
Share holders equity per share	9.84	10.09	11.91	27.69	23.93
Interest debt per share	16.16	15.11	16.53	22.62	19.75
Market cap	96.07B	132.41B	133.78B	166.31B	209.65B
Enterprise value	110.44B	145.26B	146.33B	190.76B	232.71B
P/E ratio	44.58	99.18	41.86	1.48K	63.76
Price to sales ratio	4.35	5.43	5.03	4.44	4.73
POCF ratio	36.7	44.6	27.88	27.89	21.37
PFCF ratio	77.04	260.13	61	44.2	28.97
P/B Ratio	7.71	10.09	8.56	4.24	5.66
PTB ratio	7.71	10.09	8.56	4.24	5.66
EV to sales	5	5.96	5.5	5.1	5.25
Enterprise value over EBITDA	15.3	20.7	17.48	25.22	24.95
EV to operating cash flow	42.18	48.93	30.49	31.99	23.73
EV to free cash flow	88.56	285.39	66.72	50.69	32.16
Earnings yield	0.02	0.01	0.02	0	0.02
Free cash flow yield	0.01	0	0.02	0.02	0.03
Debt to equity	3.74	3.56	3.27	1.68	1.6
Debt to assets	0.77	0.76	0.77	0.63	0.62
Net debt to EBITDA	1.99	1.83	1.5	3.23	2.47
Current ratio	0.96	0.86	0.96	1.16	0.86
Interest coverage	1.11	2.04	3.95	0.81	2.79
Income quality	1.21	1.92	1.23	-22.5	3.92
Dividend Yield	0.04	0.03	0.03	0.02	0.02
Payout ratio	1.62	2.69	1.12	34.43	1.33
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.27	0.24	0.23	0.26	0.22
Intangibles to total assets	0.56	0.53	0.49	0.59	0.61
Capex to operating cash flow	-0.52	-0.83	-0.54	-0.37	-0.26
Capex to revenue	-0.06	-0.1	-0.1	-0.06	-0.06
Capex to depreciation	-0.37	-0.65	-0.83	-0.34	-0.47
Stock based compensation to revenue	0	0	0	0	0
Graham number	19.41	15.26	25.55	7.02	33.81
ROIC	0.03	0.06	0.12	-0.01	0.08
Return on tangible assets	0.08	0.05	0.09	0	0.09
Graham Net	-31.26	-29.95	-31.32	-38.92	-32.73
Working capital	-701M	-2.55B	-763M	3.65B	-3.7B
Tangible asset value	-19.62B	-17.91B	-17.15B	-23.1B	-22.07B
Net current asset value	-31.02B	-31.22B	-31.55B	-39.83B	-36.83B
Invested capital	1.53	1.39	1.3	0.78	0.79
Average receivables	0	0	0	0	0
Average payables	2.67B	7.85B	14.89B	17.36B	18.99B
Average inventory	2.96B	3.04B	3.61B	6.5B	6.84B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	127.19	1.04K	1.09K	555.79	560.86
Days of inventory on hand	213.71	236.83	277.18	263.63	138.42
Receivables turnover	0	0	0	0	0
Payables turnover	2.87	0.35	0.34	0.66	0.65
Inventory turnover	1.71	1.54	1.32	1.38	2.64
ROE	0.17	0.1	0.2	0	0.09
Capex per share	-1.08	-1.89	-1.99	-1.55	-1.66

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
Revenue per share	7.36	6.95	7.09	7.23	7.02
Net income per share	0.25	0.23	1.06	0.58	1.16
Operating cash flow per share	2.09	0.81	1.89	1.55	2.02
Free cash flow per share	1.85	0.46	1.18	1.19	1.07
Cash per share	3.76	3.15	3.16	4.13	4.17
Book value per share	23.48	23.2	22.7	23.91	23.1
Tangible book value per share	-16.07	-15.35	-15.59	-14.25	-15.16
Share holders equity per share	23.48	23.2	22.7	23.91	23.1
Interest debt per share	20.31	19.26	19.15	19.1	20.57
Market cap	205.73B	203.83B	172.48B	209.78B	217.39B
Enterprise value	231.07B	228.55B	197.32B	232.85B	242.66B
P/E ratio	133.25	141.55	26.29	58.21	30.14
Price to sales ratio	18.06	18.92	15.71	18.72	19.98
POCF ratio	63.65	163.33	58.87	87.48	69.39
PFCF ratio	71.71	289.13	94.82	113.76	130.72
P/B Ratio	5.66	5.67	4.91	5.66	6.07
PTB ratio	5.66	5.67	4.91	5.66	6.07
EV to sales	20.29	21.22	17.97	20.78	22.31
Enterprise value over EBITDA	105.13	119.35	71.52	204.61	62.41
EV to operating cash flow	71.49	183.13	67.34	97.1	77.45
EV to free cash flow	80.54	324.18	108.48	126.27	145.92
Earnings yield	0	0	0.01	0	0.01
Free cash flow yield	0.01	0	0.01	0.01	0.01
Debt to equity	1.76	1.69	1.68	1.6	1.7
Debt to assets	0.64	0.63	0.63	0.62	0.63
Net debt to EBITDA	11.53	12.9	9	20.27	6.5
Current ratio	1	0.96	0.81	0.86	0.9
Interest coverage	2.61	1.73	3.67	-0.95	6.98
Income quality	5.84	5.05	3.17	3.08	1.39
Dividend Yield	0.01	0	0.01	0	0.01
Payout ratio	7.7	0	0.85	0	1.69
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.19	0.24	0.21	0.23	0.24
Intangibles to total assets	0.61	0.62	0.63	0.61	0.61
Capex to operating cash flow	-0.11	-0.44	-0.38	-0.23	-0.47
Capex to revenue	-0.03	-0.05	-0.1	-0.05	-0.14
Capex to depreciation	-0.28	-0.4	-0.83	-0.37	-0.98
Stock based compensation to revenue	0	0	0	0	0
Graham number	11.48	11.01	23.26	17.69	24.6
ROIC	0.01	0.01	0.03	-0.01	0.03
Return on tangible assets	0.01	0.01	0.05	0.02	0.05
Graham Net	-35.06	-33.98	-33.33	-32.71	-33.53
Working capital	-93M	-898M	-4.63B	-3.7B	-2.59B
Tangible asset value	-24.87B	-23.77B	-24.14B	-22.07B	-23.48B
Net current asset value	-41.27B	-39.71B	-38.81B	-36.83B	-38.61B
Invested capital	0.86	0.82	0.83	0.79	0.88
Average receivables	0	0	0	0	0
Average payables	18.4B	17.84B	17.76B	18.37B	19.13B
Average inventory	8.3B	6.92B	5.65B	4.89B	4.83B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	457.92	534.99	534.02	590.9	907.56
Days of inventory on hand	195.43	186.72	153.26	145.83	234.66
Receivables turnover	0	0	0	0	0
Payables turnover	0.2	0.17	0.17	0.15	0.1
Inventory turnover	0.46	0.48	0.59	0.62	0.38
ROE	0.01	0.01	0.05	0.02	0.05
Capex per share	-0.23	-0.35	-0.72	-0.36	-0.95

ZEG.DE Dividend History

ZEG.DE Frequently Asked Questions

What is AstraZeneca PLC stock symbol ?

AstraZeneca PLC is a GB stock and trading under the symbol ZEG.DE

What is AstraZeneca PLC stock quote today ?

AstraZeneca PLC stock price is $136.8 today.

Is AstraZeneca PLC stock public?

Yes, AstraZeneca PLC is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 6.27K
Market Capitalization 215.9B
Employee 83.5K
CEO Mr. Pascal Soriot D.V.M., M.B.A.
Headquarters Cambridge,GB
IPO Date 2007-09-21
Website https://www.astrazeneca.com

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.